A 2026 national survey of Dutch emergency physicians found wide variation in first-line medication choices for extreme agitation: without intravenous access, 34.7% preferred midazolam, 23.1% preferred droperidol, 14.3% preferred droperidol plus midazolam, and 10.4% preferred esketamine.1 The result is a practice map, not an outcome trial, but it shows how emergency clinicians are balancing rapid …
A 2026 study of Hodgkin lymphoma survivors treated with mantle radiation found obstructive sleep apnea (OSA) in 36 of 42 people who eventually underwent sleep testing. The practical screening target is a younger, non-obese, positional, hypopnea-heavy post-radiation OSA phenotype that standard risk heuristics can miss.1 Research Highlights Sleep symptoms identified a fatigued subgroup: 45 of …
A 2026 FAERS pharmacovigilance study of 28,938 dystonia reports found the strongest reporting signal for metoclopramide, while antipsychotics dominated the high-volume psychiatric medication signal and most timed cases began within 30 days of drug exposure.1 Research Highlights 28,938 dystonia reports: Chen et al. analyzed 27,618 patients represented in FAERS reports from Q1 2004 through Q3 …
An 11-person case series tested delayed-release apple cider vinegar capsules in young adults who had gained weight while taking psychotropic medications, and metabolic markers carried more signal than weight loss. Research Highlights Feasibility was the strongest result: 11 of 12 enrolled participants completed the study, 10 of 11 completers missed 5 or fewer doses, and …
A 2026 Neurological Sciences brief communication added 2 Tourette syndrome cases of aripiprazole-related oculogyric crisis — sustained, involuntary upward eye deviation from extraocular-muscle dystonia — after titration to 20 mg and 30 mg daily, with remission after dose reduction.1 Research Highlights 2 new Tourette cases: Cavanna et al. reported oculogyric crisis in females aged 16 …
A 2026 cross-species metabolism study found that eutylone, a synthetic cathinone stimulant sometimes sold as a “bath salt” or MDMA-like drug, inactivated CYP2D6 with Ki = 4.2 μM, kinact = 0.069 min-1, and inactivation efficiency = 1.64 x 10-2 min-1 μM-1 — a range the researchers described as comparable to MDMA. Research Highlights CYP2D6 was …
A 2026 individual participant data meta-analysis of 1,721 dementia trial participants linked risperidone to cerebrovascular adverse events, HR 4.11 (95% CI 1.77 to 9.51), and major cardiovascular adverse events, HR 2.00 (95% CI 1.23 to 3.26).1 The timing signal is the practical warning: median first cerebrovascular event appeared at 4.3 weeks, and median first major …